Designed to Predict Patient Success

The Pulmonx portfolio of diagnostics and therapeutics for emphysema enables physicians to successfully predict outcomes and provide optimal treatment for each individual patient.


Chartis® System:

The Chartis System is a pulmonary assessment tool used prior to the Zephyr EBV procedure to identify those patients with low or no collateral ventilation, who are proven to be the most likely to respond to the treatment.

Learn more


Zephyr® Endobronchial Valve:

The Zephyr device is a tiny valve designed to reduce hyperinflation of the lungs caused by emphysema that has been proven in over a decade of clinical experience to significantly improve the lung function, exercise tolerance and quality of life for patients receiving treatment.
In a minimally invasive procedure, tiny valves are placed in the lungs to occlude airways in diseased regions and achieve lung volume reduction. As a result, the remaining healthy regions may function more efficiently, enabling better breathing and an improved quality of life for patients1,2,3. The Zephyr Endobronchial Valve is removable, preserving future therapy options.

Learn more

AeriSeal® System:

To address the needs of emphysema patients who may not be candidates for Zephyr endobronchial Pulmonx is introducing new therapeutic options such as the AeriSeal System.

The AeriSeal treatment uses a polymeric foam to block diseased regions in the lung to achieve volume reduction and improve breathing function. The treatment is designed for patients with emphysema and is independent of collateral ventilation. AeriSeal received CE mark approval at the end of 2015. AeriSeal is available in a limited release in selected centers in Europe.

Learn more


  1. Herth F. et al. Respiration. 2016 ; DOI: 10.1159/000444090.
  2. Klooster K. et al. N Engl J Med. 2015; 373: 2325-36 + Supplementary Appendix.
  3. Davey C. et al. Lancet. 2015; 386(9998):1066-1073.

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, haemoptysis, pneumonia, dyspnoea and, in rare cases, death.